According to Zacks, “Orion Oyj is a pharmaceutical company. It develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company’s core therapy consists of central nervous system disorders, oncology and respiratory. Its product pipeline includes inhaled Easyhaler(R) pulmonary drugs. Orion Oyj is headquartered in Espoo, Finland. “
Shares of ORINY stock opened at $25.05 on Wednesday. ORION OYJ/ADR has a 1 year low of $18.65 and a 1 year high of $27.00. The stock has a market cap of $7.08 billion, a PE ratio of 24.56 and a beta of 0.65. The business’s fifty day moving average is $24.74 and its 200-day moving average is $21.65. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.97 and a current ratio of 2.98.
About ORION OYJ/ADR
Orion Oyj engages in the development and manufacture of pharmaceuticals, active pharmaceutical ingredients (APIs), and diagnostic tests worldwide. The company operates in two segments, Pharmaceuticals and Diagnostics. The Pharmaceuticals segment develops, manufactures, and markets pharmaceuticals and APIs.
Featured Story: Does the Dogs of the Dow strategy work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ORION OYJ/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ORION OYJ/ADR and related companies with MarketBeat.com's FREE daily email newsletter.